Arcutis Biotherapeutics, Inc. ARQT
Regular-session close
After hours · Nov 19, 4:39 PM ET
- YTD
- -6.44%
- 1 year
- -2.58%
5D -0.04 (-0.15%)
- Market cap
- 3.44B
- Revenue (ttm)
- 508.68M
- Profit margin
- 5.88%
- EPS (ttm)
- 0.22
- Shares out
- 126.46M
- P/E ratio
- 123.50
- Forward P/E
- 24.83
- YTD return
- -6.44%
- 1-year return
- -2.58%
- 50-day average
- 27.74
- Volume
- 1.33M
- Avg volume
- 2.63M
- Open
- 27.74
- Previous close
- 27.61
- Day's range
- 26.99 – 28.09
- 52-week range
- 19.30 – 34.80
- Beta
- 1.63
- Analysts
- Strong Buy
- Price target
- 40.38 (+48.6%)
- Earnings date
- Feb 24, 2027
Key statistics
- 200-day average
- 25.40
- Enterprise value
- 3.36B
- Price / sales
- 6.75
- Price / book
- 14.03
- Revenue growth
- 45.10%
- Free cash flow
- 32.62M
- Total cash
- 259.46M
- Total debt
- 123.82M
- Return on equity
- 14.88%
- Short % of float
- 15.31%
Fundamental scorecard
12 of 25 checks passed on ARQT’s reported financials
12of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 34.00
- Target (mean)
- 40.38
- Target (high)
- 48.00
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.19714.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.21 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.18 | 0.06 | -0.12 | -66.67% |
| Aug 5, 2026 | Jun 30, 2026 | 0.05508 | 0.11 | +0.05 | +99.71% |
| May 6, 2026 | Mar 31, 2026 | -0.02 | -0.09 | -0.07 | -350.00% |
| Feb 25, 2026 | Dec 31, 2025 | 0.03 | 0.13 | +0.10 | +333.33% |
| Oct 28, 2025 | Sep 30, 2025 | -0.10 | 0.06 | +0.16 | +160.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | TD Cowen | main | Buy | Buy |
| Oct 19, 2026 | Guggenheim | main | Buy | Buy |
| Oct 15, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 6, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 6, 2026 | Guggenheim | main | Buy | Buy |
| Aug 6, 2026 | Needham | main | Buy | Buy |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arcutis.com
News
Arcutis Biotherapeutics, Inc. $ARQT Stock Bought by Aberdeen Group plc Arcutis Biotherapeutics Presents New Caregiver-Reported Outcomes Data From INTEGUMENT-INFANT Trial Supporting ZORYVE Cream 0.05%, At ACAAI Annual Scientific Meeting
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock
Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
Your note
Sign in to keep a note on ARQT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNETT PATRICK | Officer | Sale | Nov 1, 2026 | 116,649 |
| CHAUDHURI BHASKAR | Director | Stock Award(Grant) | Jun 11, 2025 | 917,807 |
| EDWARDS LARRY TODD | Officer | Sale | Mar 1, 2026 | 175,178 |
| HERON PATRICK J | Director | Stock Award(Grant) | Jun 4, 2026 | 8,868,640 |
| MATSUDA MASARU | Officer | Conversion of Exercise of derivative security | Nov 3, 2026 | 111,289 |
| PEETZ CHRISTOPHER | Director | Stock Award(Grant) | Jul 14, 2026 | 191,815 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.16% | 19,171,035 | 520.88M | Sep 29, 2026 |
| Montanova Capital LLC | 9.70% | 12,269,000 | 333.35M | Sep 29, 2026 |
| Frazier Life Sciences Management, L.P. | 7.81% | 9,874,511 | 268.29M | Sep 29, 2026 |
| Rubric Capital Management LP | 6.66% | 8,421,577 | 228.81M | Sep 29, 2026 |
| State Street Corporation | 6.10% | 7,718,628 | 209.72M | Sep 29, 2026 |
| Polar Capital Holdings PLC | 5.21% | 6,592,116 | 179.11M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.39% | 6,810,517 | 185.04M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.82% | 3,564,957 | 96.86M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.39% | 3,020,203 | 82.06M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.34% | 2,959,244 | 80.40M | Sep 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.16% | 1,466,411 | 39.84M | Sep 29, 2026 |
| Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. | 1.10% | 1,386,237 | 37.66M | Jun 29, 2026 |
